StockNews.AI
ALNY
StockNews.AI
4 hrs

Scenic Enters License and Research Agreement with Alnylam

1. ALNY engages in a new agreement with Scenic Biotech for RNAi research. 2. The collaboration validates Scenic's Cell-Seq platform in drug target discovery. 3. Scenic's innovative therapies aim to treat genetic disorders through modifier genes. 4. This is Scenic's third collaboration with major US biotech firms. 5. The partnership will enhance ALNY's pipeline of disease-modifying therapies.

4m saved
Insight
Article

FAQ

Why Bullish?

The partnership with Scenic Biotech strengthens ALNY's innovative pipeline, similar to past relations boosting stock value.

How important is it?

The collaboration is crucial for ALNY's growth, emphasizing innovative therapeutic exploration and potential market expansion.

Why Long Term?

Successful research collaboration can result in significant developments, impacting ALNY's revenue in the future.

Related Companies

GENENTECHBMY
 Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics. "Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets," said Vincent Blomen, PhD, Senior Director of Discovery Sciences at Scenic Biotech. "As we advance our pipeline of first-in-class disease-modifying therapies, we're committed to empowering our partners in developing innovative medicines for patients facing devastating conditions." This collaboration marks Scenic's third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. These collaborations harness the Cell-Seq platform's capacity to deliver genetic insights that drive novel therapeutic discovery and development. While Scenic focuses primarily on identifying modifier genes, the technology has proven its ability to map unexplored biological pathways and investigate disease mechanisms. About Scenic BiotechScenic Biotech is advancing modifier therapy, a radical new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another gene that can improve or in some cases even bypass the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-Seq platform, includes small molecule programs that are wholly owned. In addition, our platform is leveraged through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic Biotech is developing a range of modifier therapies to help patients. For more information, please contact: Scenic BiotechOscar Izeboud, PhD, CEOPhone: +31 20 7059 990Email: info@scenicbiotech.com Trophic Communications Eva Mulder & Desmond JamesPhone: +31 65 2331 579Email: scenic@trophic.eu

Related News